Cargando…

Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye

This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of uveitis and uveitic macular oedema. The drug is available at low cost but it is associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikhail, Michael, Sallam, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medical Hypothesis, Discovery & Innovation Ophthalmology 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017635/
https://www.ncbi.nlm.nih.gov/pubmed/24822232
_version_ 1782479987971981312
author Mikhail, Michael
Sallam, Ahmed
author_facet Mikhail, Michael
Sallam, Ahmed
author_sort Mikhail, Michael
collection PubMed
description This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of uveitis and uveitic macular oedema. The drug is available at low cost but it is associated with a high risk of raised intraocular pressure (IOP) and cataract and is not licensed for intraocular use. Dexamethasone implant (Ozurdex®) appears to have a better safety profile, and a slightly long-lasting effect than triamcinolone acetonide. Fluocinolone acetonide implant (Retisert®) implant allows the release of corticosteroids at a constant rate over a 3-year period, but it requires surgical placement and its use is associated with a very high risk of cataracts and raised intraocular pressure. Iluvien® is another fluocinolone acetonide implant that could represent a more convenient treatment option for such cases in the future as it can be inserted into the vitreous cavity through 25-gauge injector system in an outpatient setting. To circumvent the risks associated with corticosteroids use, non-corticosteroids related therapeutics including intravitreal methotrexate; anti-vascular endothelial growth factor treatments and intravitreal sirolimus have been recently developed.
format Online
Article
Text
id pubmed-4017635
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medical Hypothesis, Discovery & Innovation Ophthalmology
record_format MEDLINE/PubMed
spelling pubmed-40176352014-05-12 Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye Mikhail, Michael Sallam, Ahmed Med Hypothesis Discov Innov Ophthalmol Review This article reviews the new clinically relevant data regarding the intraocular treatment of non-infectious uveitis. Triamcinolone acetonide is the most commonly used intravitreal corticosteroid for treatment of uveitis and uveitic macular oedema. The drug is available at low cost but it is associated with a high risk of raised intraocular pressure (IOP) and cataract and is not licensed for intraocular use. Dexamethasone implant (Ozurdex®) appears to have a better safety profile, and a slightly long-lasting effect than triamcinolone acetonide. Fluocinolone acetonide implant (Retisert®) implant allows the release of corticosteroids at a constant rate over a 3-year period, but it requires surgical placement and its use is associated with a very high risk of cataracts and raised intraocular pressure. Iluvien® is another fluocinolone acetonide implant that could represent a more convenient treatment option for such cases in the future as it can be inserted into the vitreous cavity through 25-gauge injector system in an outpatient setting. To circumvent the risks associated with corticosteroids use, non-corticosteroids related therapeutics including intravitreal methotrexate; anti-vascular endothelial growth factor treatments and intravitreal sirolimus have been recently developed. Medical Hypothesis, Discovery & Innovation Ophthalmology 2013 /pmc/articles/PMC4017635/ /pubmed/24822232 Text en © 2013, Medical Hypothesis, Discovery & Innovation (MEHDI) Ophthalmology Journal This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Mikhail, Michael
Sallam, Ahmed
Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
title Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
title_full Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
title_fullStr Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
title_full_unstemmed Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
title_short Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye
title_sort novel intraocular therapy in non-infectious uveitis of the posterior segment of the eye
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017635/
https://www.ncbi.nlm.nih.gov/pubmed/24822232
work_keys_str_mv AT mikhailmichael novelintraoculartherapyinnoninfectiousuveitisoftheposteriorsegmentoftheeye
AT sallamahmed novelintraoculartherapyinnoninfectiousuveitisoftheposteriorsegmentoftheeye